Goldman, S.C., Holcenberg, J.S., Finklestain, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. and Cario, M. S. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
 Bose, P. and Qubaiah, O. (2011) A review of tumor lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics, 36, 299-326. http://dx.doi.org/10.1111/j.1365-2710.2011.01260.x
 Cairo, M.S., Coiffier, B., Reiter, A. and Younes, A. (2010) Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant disease: An expert TLS panel consensus. British Journal of hematology, 149, 578-586.
 Jeha, S., Kantarijian, H., Irwin, D., Shen, V., Shenoy, S., Blaney, B., Camitta, B. and Pui, C.H. (2005) Efficacy and safety of rasbricase, a recombinant urate oxidase, in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. Leukemia, 19, 34-38.
 Cammalleri, L. and Malaguarnera, M. (2007) Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. International Journal of Medical sciences, 4, 83-93. http://dx.doi.org/10.7150/ijms.4.83
 Trifilio, S., Gordon, L., Singhal, S., Tallman, M., Evans, A., Rashid, K., Fishman, M., Mashio, K., Pi, J. and Mehta, J. (2006) Reduced-dose rasbricase in adult cancer patients with hyperuricemia. Bone Marrow Transplantation, 26, 806-812.